Analysts have clear opinions on PCRX.

There are 4 analysts on the Wall offering 12 month price targets for Pacira Pharmaceuticals in the last 3 months. The average price target is $62.75 with a high forecast of $85.00 and a low forecast of $41.00. The average price target represents a 27.90% increase from the last price of $49.06.
Pacira BioSciences, Inc. (PCRX) is followed by 4 analysts on the street.

Gregg Gilbert from SunTrust Robinson rates it a Buy with a target of $60.00.

Similarly, Last month Boris Peaker of Cowen & Co. Assigned a Hold with a target of $41.00.

The consensus on the street is null.

What does Pacira BioSciences, Inc.(PCRX) do ?
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Pacira BioSciences, Inc. (PCRX) Insider Trades

Looking for stocks just like PCRX?

Based on Wall Street analyst research, several stocks are similar to PCRX
They are:
– CARA [Info can be found here: ]
– AVDL [Info can be found here: ]
– DRRX [Info can be found here: ]